Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + folinic acid + fluorouracil + oxaliplatin
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Amivantamab + folinic acid + fluorouracil + oxaliplatin is an investigational combination regimen consisting of the bispecific monoclonal antibody amivantamab (Rybrevant) and the standard FOLFOX chemotherapy regimen (folinic acid, fluorouracil, and oxaliplatin). Developed by Johnson & Johnson, this combination is being evaluated for the treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Amivantamab targets both the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptor pathways, aiming to overcome resistance mechanisms associated with standard anti-EGFR therapies. The chemotherapy components provide cytotoxic activity: fluorouracil acts as an antimetabolite that inhibits thymidylate synthase (potentiated by folinic acid), while oxaliplatin is a platinum-based alkylating agent that induces DNA damage. This combination is currently being evaluated in Phase 3 clinical trials (such as the OrigAMI-2 study) as a first-line treatment for patients with unresectable or metastatic left-sided colorectal cancer.
- Other names
- Rybrevant + FOLFOXRybrevant + mFOLFOX6amivantamab + FOLFOXamivantamab + mFOLFOX6amivantamab plus FOLFOXamivantamab plus mFOLFOX6
02
Targets
DNAEGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on amivantamab + folinic acid + fluorouracil + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + folinic acid + fluorouracil + oxaliplatin.